Changzheng Chen, PhD

Employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey

  • 4Articles
  • 12.9KReads1
  • 2013–2026Active
  • 14Collaborators
  • 73Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Changzheng Chen, PhD, is affiliated with Intra-Cellular Therapies, a Johnson & Johnson Company, in Bedminster, New Jersey. The author has published on clinical trials investigating pharmacological treatments for major depressive disorder (MDD), including studies on lumateperone as adjunctive therapy and levomilnacipran extended-release formulations. Research topics focus on efficacy, safety, and functional outcomes in patients with MDD. Collaborations include frequent co-authors Carl P. Gommoll, William M. Greenberg, Adam Ruth, Andrew J. Cutler, and Anjana Bose.

Publications

JCP
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress

September 14, 2026

Adjunctive lumateperone 42 mg significantly improved depression and anxiety symptoms in patients with MDD with inadequate antidepressant response and anxious distress
, , , et al
JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al
PCC
Article

Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories

June 11, 2015

Reducing functional impairment in patients with major depressive disorder is critical for optimizing treatment outcomes and achieving long-term wellness. In this post hoc analysis, improvement in functional impairment in...
, , , et al
JCP
Original Research

Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

March 15, 2013

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe